Liraglutide ameliorates myocardial damage in experimental diabetic rats by inhibiting pyroptosis via Sirt۱/AMPK signaling

Publish Year: 1400
نوع سند: مقاله ژورنالی
زبان: English
View: 153

This Paper With 8 Page And PDF Format Ready To Download

  • Certificate
  • من نویسنده این مقاله هستم

استخراج به نرم افزارهای پژوهشی:

لینک ثابت به این Paper:

شناسه ملی سند علمی:

JR_IJBMS-24-10_005

تاریخ نمایه سازی: 11 مهر 1400

Abstract:

Objective(s): Liraglutide, a well-established drug for treating diabetes mellitus (DM), has recently gained attention for its cardiovascular benefits in diabetes via multiple cellular activities; however, whether liraglutide improves myocardial damage by inhibiting pyroptosis and the mechanisms of these potential effects remain unknown.Materials and Methods: In this study, high-fat diet feeding and low-dose streptozotocin (STZ) injection were used to construct a rat DM model. Rats with fasting blood glucose (FBG) levels >۱۶.۷ mmol/l received subcutaneous injections of liraglutide (۰.۲ mg/kg) for ۴ weeks. Metabolic parameters, the heart weight/body weight (HW/BW) ratio, and histopathology were examined. Protein levels of inflammatory, pyroptosis, and NOD-like receptor protein ۳ (NLRP۳) inflammasome markers were assessed via Western blotting. In in vitro studies, a sirtuin ۱ (Sirt۱) inhibitor (EX ۵۲۷, ۲۰۰ nM) and an AMP-activated protein kinase (AMPK) inhibitor (compound C, ۲۰ µM) were used to inhibit Sirt۱ and AMPK pathways, respectively.Results: Liraglutide significantly attenuated cardiac hypertrophy, pathological changes, inflammation, pyroptosis, and NLRP۳ inflammasome activation, accompanied by increased Sirt۱ and AMPK activation. Consistent with the in vivo results, liraglutide attenuated high glucose (HG)-induced pyroptosis and NLRP۳ inflammasome activation along with enhanced Sirt۱ and AMPK activation. After blockade of Sirt۱ and AMPK signaling, the protective effect of liraglutide was restrained. Notably, EX ۵۲۷ abolished the stimulatory effect of liraglutide on Sirt۱ and AMPK signaling, whereas compound C blunted AMPK signaling without affecting Sirt۱ signaling. Conclusion: Liraglutide may protect against myocardial damage by activating the Sirt۱/AMPK signaling pathways to inhibit cellular pyroptosis in DM.

Authors

Zhe Zhang

Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang ۰۵۰۰۵۱, P.R. China

Xing Wang

Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang ۰۵۰۰۵۱, P.R. China

Linlin Yang

Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang ۰۵۰۰۵۱, P.R. China

Linquan Yang

Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang ۰۵۰۰۵۱, P.R. China

Huijuan Ma

Hebei Key Laboratory of Metabolic Diseases, Hebei General Hospital, Shijiazhuang ۰۵۰۰۵۱, P.R. China

مراجع و منابع این Paper:

لیست زیر مراجع و منابع استفاده شده در این Paper را نمایش می دهد. این مراجع به صورت کاملا ماشینی و بر اساس هوش مصنوعی استخراج شده اند و لذا ممکن است دارای اشکالاتی باشند که به مرور زمان دقت استخراج این محتوا افزایش می یابد. مراجعی که مقالات مربوط به آنها در سیویلیکا نمایه شده و پیدا شده اند، به خود Paper لینک شده اند :
  • Sardu C, De Lucia C, Wallner M, Santulli G. Diabetes ...
  • Jiang YX, Li W, Wang J, Wang GG. Cardiac dysfunction ...
  • Atta MS, El-Far AH, Farrag FA, Abdel-Daim MM, Al Jaouni ...
  • El Husseny MW, Mamdouh M, Shaban S, Ibrahim Abushouk A, ...
  • Zhou W, Chen C, Chen Z, Liu L, Jiang J, ...
  • Luo B, Huang F, Liu Y, Liang Y, Wei Z, ...
  • Wu M, Han W, Song S, Du Y, Liu C, ...
  • Huang Z, Zhuang X, Xie C, Hu X, Dong X, ...
  • Luo B, Li B, Wang W, Liu X, Xia Y, ...
  • Altamimi JZ, Alfaris NA, Alshammari GM, Alagal RI, Aljabryn DH, ...
  • Jiang T, Jiang D, Zhang L, Ding M, Zhou H. ...
  • Luo G, Jian Z, Zhu Y, Zhu Y, Chen B, ...
  • Wang S, Wang Y, Zhang Z, Liu Q, Gu J. ...
  • Haye A, Ansari MA, Rahman SO, Shamsi Y, Ahmed D, ...
  • Lambadiari V, Pavlidis G, Kousathana F, Varoudi M, Vlastos D, ...
  • Zhang L, Li C, Zhu Q, Li N, Zhou H. ...
  • Zhang Q, Xiao X, Zheng J, Li M, Yu M, ...
  • Zhang Y, Ling Y, Yang L, Cheng Y, Yang P, ...
  • Nauck MA, Meier JJ, Cavender MA, Abd El Aziz M, ...
  • Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, ...
  • Zhu ZD, Ye JM, Fu XM, Wang XC, Ye JY, ...
  • Zuurbier CJ. NLRP۳ inflammasome in cardioprotective signaling. J Cardiovasc Pharmacol ...
  • Tavakoli Dargani Z, Singla DK. Embryonic stem cell-derived exosomes inhibit ...
  • Chen A, Chen Z, Xia Y, Lu D, Yang X, ...
  • Kane AE, Sinclair DA. Sirtuins and NAD+ in the development ...
  • Ma S, Feng J, Zhang R, Chen J, Han D, ...
  • Fang WJ, Wang CJ, He Y, Zhou YL, Peng XD, ...
  • Luo W, Jin Y, Wu G, Zhu W, Qian Y, ...
  • Ying Y, Jiang C, Zhang M, Jin J, Ge S, ...
  • Yao R, Cao Y, Wang C, Xu L, Zhang X, ...
  • Lin C, Zhang M, Zhang Y, Yang K, Hu J, ...
  • Wei H, Bu R, Yang Q, Jia J, Li T, ...
  • Liu L, Liu C, Fang L. AMPK-SIRT۱ pathway dysfunction contributes ...
  • Dong HW, Zhang LF, Bao SL. AMPK regulates energy metabolism ...
  • Pal PB, Sonowal H, Shukla K, Srivastava SK, Ramana KV. ...
  • Manna P, Achari AE, Jain SK. Vitamin D supplementation inhibits ...
  • Wang L, Quan N, Sun W, Chen X, Cates C, ...
  • نمایش کامل مراجع